Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402713 | 0.87 | GSK3B (0.76) | GSK3BMAPTCYP3A4KDM4EALDH1A1 | |
| SCHEMBL2403904 | 0.84 | GSK3B (0.75) | GSK3BCYP2D6 | |
| SCHEMBL5105275 | 0.84 | GSK3B (0.61) | GSK3BMAPT | |
| SCHEMBL2403885 | 0.84 | GSK3B (0.81) | GSK3B | |
| SCHEMBL2405613 | 0.84 | GSK3B (0.81) | GSK3B | |
| SCHEMBL2403556 | 0.83 | GSK3B (0.70) | GSK3B | |
| SCHEMBL2404400 | 0.83 | GSK3B (0.79) | GSK3BCYP3A4 | |
| SCHEMBL5038068 | 0.83 | GSK3B (0.79) | GSK3B | |
| SCHEMBL2404034 | 0.83 | GSK3B (0.79) | GSK3BCYP3A4 | |
| SCHEMBL5045756 | 0.83 | GSK3B (0.79) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | claimed |
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI (FR) | 2005-06-16 | — | — | US | claimed |
| US-6844335-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives as GSK3.β.inhibitors | SANOFI-SYNTHELABO (FR) | 2005-01-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130998-A1 | 2-amino-3-(alkyl)-pyrimidone derivatives | GSK3A, GSK3B, PSEN2 | GSK3B 2/4885SMN1; SMN2 645/4885PKM 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.